Antigen-Specific Antibody Sequencing via High-Throughput DNA Analysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for identifying and producing monoclonal antibodies are complex, time-consuming, and limited to a few species, as they require extensive information on immunoglobulin repertoires and are inefficient in expressing antibodies specific to pathogens or cancer cells, especially when using E. coli expression systems due to codon usage issues and the need for myeloma cell lines which are difficult to develop.
Innovation Solution
A method involving high-throughput DNA sequencing of immunoglobulin DNA from immunized animals to identify antigen-specific antibody sequences by determining nucleic acid sequences of VH and VL regions from peripheral blood or lymphoid tissues, allowing for the generation of antigen-specific antibodies without the need for myeloma cell lines or extensive separation of B cells, using bioinformatic analysis and chemical synthesis of antibody sequences.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If hybridoma technology is used to produce monoclonal antibodies, then monoclonal antibodies can be obtained, but the process is time-consuming (2-6 months) and limited to a few species
Solution Approach 1:
The patent performs preliminary sequencing of immunoglobulin variable region genes from B cells before antibody production. By pre-identifying and characterizing the antibody gene sequences (VH and VL regions) through high-throughput sequencing, the method prepares all necessary genetic information in advance, allowing direct synthesis and expression of monoclonal antibodies without the time-consuming hybridoma formation and screening process that normally takes 2-6 months.
Solution Approach 2:
The patent replaces the mechanical/cellular hybridoma fusion process with a molecular biology approach. Instead of fusing B cells with myeloma cells and performing manual screening, the method uses high-throughput DNA sequencing to identify antibody genes, followed by in vitro gene synthesis and expression. This substitution of cellular manipulation with molecular sequencing and synthetic biology techniques dramatically reduces the time required while expanding applicability to multiple species.
2Productivity
If E. coli is used to express antibody libraries, then high-throughput screening is possible, but codon usage incompatibility prevents expression of many human antibodies
Solution Approach 1:
The patent changes the expression system from E. coli to mammalian cells (such as HEK293 cells). This parameter change in the host organism resolves the codon usage incompatibility issue, as mammalian cells naturally process human antibody genes with their native codon usage patterns. The patent specifically mentions expressing antibody libraries in mammalian cells to overcome the limitations of bacterial expression systems, thereby achieving both high throughput and reliable expression of human antibodies.
3Adaptability or versatility
If extensive information on immunoglobulin repertoires is required for antibody isolation, then species-specific methods can be developed, but the complexity and time required increase significantly
Solution Approach 1:
The patent employs a universal high-throughput sequencing approach that can identify and characterize immunoglobulin variable region genes across multiple species simultaneously. By using degenerate primers and bioinformatic analysis that accommodate species variation, the method creates a universal platform applicable to mice, humans, and other animals without requiring separate, species-specific protocols. This universality reduces overall complexity while expanding adaptability to different species.
4Reliability
If myeloma cell lines are developed for each species, then stable hybridomas can be produced, but the development process is difficult and time-consuming
Solution Approach 1:
The patent replaces the entire hybridoma formation process (which requires developing species-specific myeloma cell lines) with a direct gene synthesis and expression approach. By sequencing the antibody genes from B cells and synthesizing the corresponding cDNA in vitro, the method eliminates the need for myeloma cell fusion and stabilization. The antibody genes are directly cloned into expression vectors and transfected into mammalian cells, bypassing the complex and time-consuming myeloma cell line development process entirely.
Data Source
AI summary
Methods and compositions for identification of candicate antigen-specific variable regions as well as generation of antibodies or antigen-binding fragments that could have desired antigen specificity are provided. For example, in certain aspects methods for determining amino acid sequences of serum antibody CDR and abundancy level are described. In some aspects, methods for determining nucleic acid sequences of antibody variable region sequences and frequency are provided. Furthermore, the invention provides methods for identification and generation of antibody or antigen-binding fragments that comprise highly-represented CDR.